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ABSTRACT
Objectives We aimed to examine the relationship
between access to medicine for cardiovascular disease
(CVD) and major adverse cardiovascular events (MACEs)
among people at high risk of CVD in high-income countries
(HICs), upper and lower middle-income countries (UMICs,
LMICs) and low-income countries (LICs) participating in the
Prospective Urban Rural Epidemiology (PURE) study.
Methods We defined high CVD risk as the presence of
any of the following: hypertension, coronary artery disease,
stroke, smoker, diabetes or age >55 years. Availability
and affordability of blood pressure lowering drugs,
antiplatelets and statins were obtained from pharmacies.
Participants were categorised: group 1—all three drug
types were available and affordable, group 2—all three
drugs were available but not affordable and group 3—all
three drugs were not available. We used multivariable
Cox proportional hazard models with nested clustering at
country and community levels, adjusting for comorbidities,
sociodemographic and economic factors.
Results Of 163 466 participants, there were 93 200
with high CVD risk from 21 countries (mean age 54.7,
49% female). Of these, 44.9% were from group 1, 29.4%
from group 2 and 25.7% from group 3. Compared with
participants from group 1, the risk of MACEs was higher
among participants in group 2 (HR 1.19, 95% CI 1.07 to
1.31), and among participants from group 3 (HR 1.25, 95%
CI 1.08 to 1.50).
Conclusion Lower availability and affordability of essential
CVD medicines were associated with higher risk of MACEs
and mortality. Improving access to CVD medicines should
be a key part of the strategy to lower CVD globally.
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BACKGROUND
Although cardiovascular disease (CVD)
mortality has decreased in high-
income

Key questions
What is already known?
►► Our previous study, using data from cross-sectional

surveys at baseline in Prospective Urban Rural
Epidemiology study, showed that those with cardiovascular disease (CVD) living in communities where
medicines are unavailable or unaffordable are less
likely to be on treatment or to have their blood pressure controlled.
►► However, no study has prospectively documented
the impact of availability and affordability of CVD
medicines on CVD outcomes.

What are the new findings?
►► We found that essential CVD medicines were un-

available and unaffordable for a large proportion of
communities where the individuals with a high risk
of CVD were living, particularly in lower-
middle-
income and low-income countries.
►► After accounting for sociodemographic and economic factors, education and comorbidities, the unavailability and unaffordability of essential CVD medicines
were associated with a higher risk of major adverse
cardiovascular events.
►► Our analyses are unique because we used standardised methods to assess availability, affordability
and event rates in 21 countries and 592 urban and
rural communities.

countries (HICs), it has remained high in
lower-income countries (LICs) and middle-
income countries,1 threatening the achievement of the United Nation’s Sustainable
Development Goal 3, which includes a target
to reduce premature mortality from non-
communicable disease by a third by 2030.2

Chow CK, et al. BMJ Global Health 2020;5:e002640. doi:10.1136/bmjgh-2020-002640



1

BMJ Global Health
Key questions
What do the new findings imply?
►► These findings highlight the importance of ensuring the availability

and affordability of essential CVD medicines globally, especially in
LMICs. This is in line with the WHO’s ‘Global Action Plan for the
Prevention and Control of NCDs 2013–2020’ which has a set target
of 80% availability of affordable essential medicines for NCDs, with
least 50% of the eligible people receiving such treatment.
►► The study findings imply that affordability in particular is crucial in
high, middle-income and low-income settings, and hence likely that
without affordable access to essential cardiovascular medicines, it
will continue to be a barrier to good medication compliance and
cardiovascular outcomes.

Access to affordable and effective medicines has contributed to the decline in HICs, but they are either unavailable or unaffordable for many people living in middle-
income countries and LICs.3 4 The WHO and World
Heart Federation have set a goal towards achieving the
target that at least 50% of eligible people receive drug
therapy and counselling to prevent heart attacks and
stroke.5
We have previously shown, using data from cross-
sectional surveys at baseline in the Prospective Urban
and Rural Epidemiology (PURE) study, that those with
CVD living in communities where medicines are unavailable or unaffordable are less likely to be on treatment3 or
to have their blood pressure (BP) controlled.6 However,
no study has followed up populations in HIC, middle-
income countries and LICs over time to quantify any
impact of availability and affordability of CVD medicines
on CVD outcomes. Follow-up data from PURE are now
available, making it possible, for the first time using
consistent methods in HICs, middle-
income countries
and LICs, to answer this question.
METHODS
Study design and participants
We analysed data from the PURE study, which has now
recruited 192 550 participants aged 35–70 years from 23
countries. Follow-up data are now available for 174 345
participants from 21 countries (follow-up is still ongoing
in the remaining participants). We included participants
with complete follow-up data for this analysis. We also
used the linked EPOCH (the Environmental Proﬁle of a
Community’s Health) data (n=1 63 466), which captures
objective and subjective measures of environmental and
societal factors that can influence CVD in the communities where PURE is undertaken.7 The EPOCH instrument
comprised of two parts: EPOCH 1 is an objective environmental audit tool in which trained researchers directly
observe and systematically record physical aspects of
the environment using a pro-forma, with standardised
operational definitions, and EPOCH 2 is an interviewer
administered questionnaire that captures perceptions
2

about the community from PURE participants living in
that community.
Participants were defined as having high risk of CVD
if they had any of the following conditions: history of
hypertension, coronary artery disease, stroke, diabetes,
age >55, former or current smoker.8
PURE recruited participants from different HICs,
middle-income countries and LICs, making it possible
to investigate the impact of availability and affordability
of CVD medicines on adverse health outcomes across
communities at varying economic levels. The countries
included in the PURE study represented countries in
various stages of economic development (table 1). The
countries were grouped based on the World Bank income
classification in 2006 when the study was initiated. We
recognise that a few countries changed their income
category over the course of the study but for simplicity,
all countries remain in their original income categories. Details of the PURE study design were described in
previous publications.3 6 9–11
Data collection
Data on availability and costs of medicines were obtained
using the EPOCH instrument. One community pharmacy in each community was visited to collect information about availability and costs of medicines.7 12 Field
researchers were instructed to gather information for
a list of medications and if more than one medication
trade brand existed, to collect information about the
most common trade name for each of these medicine
classes as identiﬁed by the pharmacist.
As previously described, the baseline data collection
for PURE was conducted by trained interviewers using
standardised questionnaires to obtain information at the
household and individual levels. At the household level,
this included information on income and expenditure
on food per month, and at individual level, this included
sociodemographic information, medical history, CVD
risk factors and medicine use.10 Medication lists were
collected for all participant at baseline. Regular medication use was defined as taking medicine at least once per
week in the last month. Medications were recorded by
trained staff who were instructed to directly inspect the
medication or prescriptions.9 Medicines were centrally
coded into medicine classes.
Definition of essential CVD medicines
In this study, 10 medications were defined as essential
CVD medicines: captopril, enalapril, ramipril, metoprolol, atenolol, amlodipine, hydrochlorothiazide,
simvastatin, atorvastatin and aspirin.9 13 These 10
medications were categorised into three types: (1) BP
lowering drugs (captopril, enalapril, ramipril, metoprolol, atenolol, amlodipine and hydrochlorothiazide),
(2) antiplatelets (aspirin) and (3) statins (atorvastatin
and simvastatin).
Chow CK, et al. BMJ Global Health 2020;5:e002640. doi:10.1136/bmjgh-2020-002640
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Table 1 Countries included in this study with number of communities, households and participants at high cardiovascular
risk

Total
High-income countries

Number of
communities

Number of
households

All participants

Number of participants at
high CVD risk (% of all)

592
113

74 281
9815

150 185
17 214

93 200
12 032

 Canada

69

6158

10 314

7461 (72.3)

 Saudi Arabia

18

636

1494

760 (50.9)

 Sweden

23

2372

3907

3011 (77.1)

 United Arab Emirates
Upper middle-income countries

3

649

1499

117

21 440

39 180

800 (53.4)
27 189

 Argentina

20

4305

7509

5558 (74.0)

 Brazil

14

3636

6079

4625 (76.1)

 Chile

5

1934

3521

2634 (74.8)

28

6525

12 954

7901 (61.0)

4

1294

2031

1662 (81.8)

 Malaysia
 Poland
 South Africa
 Turkey
Lower middle-income countries

8

1658

3029

1906 (62.9)

38

2088

4057

2903 (71.6)

207

28 142

59 737

35 458

 Colombia

55

3685

6896

4360 (63.2)

 China

93

19 738

42 861

25 533 (59.6)

 Iran

20

2400

6013

2904 (48.3)

 Palestine

35

1055

1574

1058 (67.2)

4

1264

2393

1603 (67.0)

Low-income countries

68

3543

7791

 Bangladesh

55

1174

2926

1410 (48.2)

 Pakistan

4

838

1713

1161 (67.8)

 Tanzania

6

818

1910

847 (44.3)

3
87

713
11 341

1242
26 263

 Philippines

 Zimbabwe
 India

18 521

808 (65.1)
14 295 (54.4%)

High risk of CVD was defined as having any of the following conditions: history of hypertension, coronary artery disease, stroke, diabetes,
age >55, former or current smoker.
CD, cardiovascular disease.

Definitions of availability and affordability of the essential
CVD medicines
We used standardised definitions to measure availability
and affordability. They are limited measures, and do not
account for other factors related to access to these medications such as cost/distance to travel to pharmacies, the
provision of free medications to some or all people in
some communities. Medications were available if they
were on the shelf of the pharmacy at the time of the visit,
and cost was the price medications were sold for. We
defined our main two exposures as follows.
Availability of essential CVD medicines was deﬁned as the
presence of all three types of essential CVD medications
(BP lowering drugs, antiplatelets and statins) at any dose
in the selected pharmacy on the day of the survey.
Affordability of essential CVD medicines was assessed using
the total monthly costs of all three types of essential CVD
medication types at standard doses and recommended
Chow CK, et al. BMJ Global Health 2020;5:e002640. doi:10.1136/bmjgh-2020-002640

frequencies.9 The lowest-cost drug in each of these three
types of essential CVD medicine was chosen for the estimation of the total monthly cost. Combined costs of the
three types were defined as affordable if they constituted less than 20% of a household’s capacity to pay as
per previous publications from PURE.3 6 14 Household
capacity-
to-
pay is the household income remaining
after basic subsistence needs, defined as the household
monthly income spent on food, have been met.15
Definition of outcomes
Primary outcomes were major adverse cardiovascular
events (MACEs)—a composite of CVD mortality, stroke,
myocardial infarction and heart failure), and all-cause
mortality. Participants and their family were contacted
at regular intervals to obtain information on specific
events. Follow-up of participants was performed at least
every 3 years. All follow-
up visits were conducted by
3
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visiting households, by telephone calls or by inviting the
participants to the central research offices to complete
the follow-up visit. Events were characterised centrally in
each country by trained physicians, using standardised
definitions, verbal autopsies and review of documents.11

cardiovascular medicines due to the large domestic pharmaceutical industry and the practice that many medicines
are available over the counter and without prescription,
as well as to particular policies, such as selective process
controls.3 14

Statistical analysis
All statistical analyses were performed with SAS V.9.4 and
R. Continuous variables were presented as mean (SD or
median, range), and categorical variables as frequency
and percentage. Data were, in some instances, presented
as groups by overall country economic status for ease of
presentation, however it is acknowledged that socioeconomic heterogeneity exists within many countries also.
Models hence account for household and individual-
level socioeconomic measures.
We examined the combination of availability and
affordability through a combined variable. Participants
were classified into three groups according to the availability and affordability of the three types of medications
(BP lowering, statin and antiplatelets): group 1—individuals from communities where all three were available
and affordable, group 2—individuals from communities
where all three were available but not affordable to them
and group 3—individuals from communities where all
three were not available. Group 1 was used as the reference group. We also performed additional analysis on
the association between the number of essential CVD
medicines available and MACEs.
Multilevel Cox proportional hazard models that
account for nested clustering at country and community
levels were applied to calculate the HRs and their 95%
CIs for MACEs and all-cause mortality. The clustering was
incorporated using a frailty model, which involves introducing a shared random effect into the proportional
hazard model for participants from the same cluster.16
Nesting of community within country was incorporated
by nesting the community random effect within the
country random effect. We adjusted for covariates as in
previous publications from the PURE study, including
age, gender, educational level, smoking status, history of
hypertension, coronary heart disease, stroke, diabetes,
number of people in household, rural/urban living and
the Global Wealth Index country specific tertiles.6 The
Wealth index was created using information collected on
the household possessions from the PURE baseline questionnaire. Items included electricity, car, computer, television, motorbike, livestock, fridge, other four-wheeler
vehicle, washing machine, stereo, bike, kitchen mixture,
phone, land and kitchen window. Binary classification of
yes/no was created for each item and then a principal
component analysis was used to extract the component with largest eigenvalue. Each household was then
assigned to a score based on factor loadings.
Data from India were presented separately from other
LICs to be consistent with previous publications from
the PURE study. India was seen to be very different
from all of the other LICs with respect to availability of

Patient and public involvement
Patients or the public were not involved in the design,
or conduct, or reporting or dissemination plans of our
research.

4

RESULTS
There were 163 466 adults with follow-up data in the
PURE database at the time of analysis (August 2019)
and among these 93 200 adults were defined as having
high risk of CVD, from 592 communities and 21 countries (table 1). Among those identified as high risk, 39
968 (42.9%) had two or more risk factors, and 53 232
(57.1%) had only one single factor among the defined
risk factors.
The mean age was 54.7 years, 49.0% were female. Baseline characteristics of these participants are presented in
table 2. Participants from communities with no medications available had the highest prevalence of poor education, low wealth index, rural living and had lower use of
preventative medications at baseline (table 2).
The percentages of individuals with high CVD risk
from communities where all three types of CVD medicines were available were 74.3% overall, 97.0% in HICs,
85.2% in UMICs, 57.8% in LMICs, 24.1% in LICs and
88.3% in India. The percentages of high CVD risk individuals from communities where all three types of CVD
medicines were available and affordable (group 1) was
44.9% overall, 94.8% in HICs, 57.2% in UMICs, 28.6%
in LMICs, 10.1% in LICs and 29.9% in India (figure 1).
Overall, BP lowering medication had the highest rate
of availability (95.1% of the communities), followed by
antiplatelets (92.9%), and 78.5% for statins. The availability of these three types of essential CVD medicines
was consistently lower in LICs compared with countries
with higher income, particularly for statins (except for
India, where medicines were relatively widely available)
(online supplemental table S1 and S2).
After 9 years of follow-up in this high-risk population,
the incidence of MACEs was 6.74% (2482/36330) in
participants in group 1 (age standardised rate 6.83%),
8.67% (1825/21065) in participants in group 2 (age
standardised rate 8.63%) and 7.99% (1583/19810) in
participants in group 3 (age standardised rate 8.06%).
Using group 1 as the reference group, the risk of MACEs
was greater in group 2 (all three types of CVD medicines
were available but not affordable), with the adjusted
HR=1.19, 95% CI 1.07 to 1.31, p<0.001 and in group 3
(all three types of CVD medicines were not available),
with the adjusted HR=1.27, 95% CI 1.08 to 1.50, p=0.004.
(figure 2)
Chow CK, et al. BMJ Global Health 2020;5:e002640. doi:10.1136/bmjgh-2020-002640

BMJ Global Health
Table 2 Baseline characteristics of participants with high risk of CVD
Total high risk
participants
n=93 200
Age (years), median (SD), missing: 2
Female, n (%), missing: 1

Group 2—
Group 1—available available but
and affordable
unaffordable
n=34 974
n=22 918

54.7 (9.6)

54.4 (9.3)

54.9 (9.7)

Group 3—
unavailable
n=20 022

Missing
n=15 286

54.5 (9.7)

55.2 (9.7)

11 419 (49.8%)

9423 (47.1%)

8237 (53.9%)

4136 (18.1%)

4679 (23.5%)

2567 (16.8%)

45 700 (49.0%)

16 621 (47.5%)

 None

13 924 (15.0%)

2542 (7.3%)

 Primary school

27 909 (30.0%)

7318 (20.9%)

7639 (33.5%)

7214 (36.2%)

5738 (37.6%)

 Secondary/high school

32 637 (35.1%)

12 661 (36.2%)

9029 (39.6%)

6536 (32.8%)

4411 (28.9%)

4432 (4.8%)

2536 (7.3%)

690 (3.0%)

589 (3.0%)

617 (4.0%)

13 740 (14.8%)

9733 (27.9%)

1269 (5.6%)

850 (4.3%)

1888 (12.4%)

147 (0.4%)

44 (0.2%)

84 (0.4%)

22 (0.1%)

7499 (21.4%)

8099 (35.4%)

9493 (47.5%)

5266 (34.8%)

Educational level, n (%), missing: 261

 Trade school
 College/university
 Unknown

297 (0.3%)

Global Wealth Index country specific tertiles, missing: 188
 Tertile 1

30 357 (32.6%)

 Tertile 2

30 676 (33.0%)

11 091 (31.7%)

7963 (34.8%)

6477 (32.4%)

5145 (34.0%)

 Tertile 3

31 979 (34.4%)

16 378 (46.8%)

6847 (29.9%)

4013 (20.1%)

4741 (31.3%)

 Former smoker

17 156 (18.6%)

9100 (26.1%)

2669 (11.8%)

2232 (11.3%)

3155 (20.8%)

 Current smoker

30 926 (33.4%)

9695 (27.8%)

8503 (37.5%)

7743 (39.2%)

4985 (32.8%)

 Never smoke

44 395 (48.0%)

16 044 (46.1%)

11 525 (50.8%)

9767 (49.5%)

7059 (46.4%)

Number of people in the household,
median (Q1, Q3) missing: 11 386

3.0 (2.0–4.0)

3.0 (2.0–5.0)

4.0 (2.0–5.0)

 Urban

53 151 (57.0%)

26 163 (74.8%)

13 208 (57.6%)

5623 (28.1%)

 Rural

40 049 (43.0%)

8811 (25.2%)

9710 (42.4%)

14 399 (71.9%)

7129 (46.6%)

History of hypertension, n (%), missing:
205

31 546 (33.9%)

12 638 (36.2%)

7592 (33.2%)

5869 (29.4%)

5447 (35.7%)

History of diabetes, n (%), missing: 159

12 522 (13.5%)

5524 (15.8%)

3182 (13.9%)

1847 (9.3%)

1969 (12.9%)

History of coronary heart disease, n (%),
missing: 172

5774 (6.2%)

2267 (6.5%)

1219 (5.3%)

1401 (7.0%)

887 (5.8%)

History of stroke, n (%), missing: 179

2547 (2.7%)

847 (2.4%)

632 (2.8%)

644 (3.2%)

424 (2.8%)

6037 (6.5%)

3114 (8.9%)

861 (3.8%)

836 (4.2%)

1226 (8.0%)

4761 (5.1%)

3189 (9.1%)

508 (2.2%)

239 (1.2%)

825 (5.4%)

20 852 (22.4%)

9517 (27.2%)

4174 (18.2%)

2967 (14.8%)

4194 (27.4%)

Smoking status, n (%), missing: 723

3.0 (2.0–5.0)

3.0 (2.0–5.0)

Urban/rural living, n (%), missing: 0
8157 (53.4%)

Use of preventative medication:
 Antiplatelets
 Statins
 BP lowering

Group 1—individuals from communities where all three were available and affordable, group 2—individuals from communities where all three
were available but not affordable to them, group 3—individuals from communities where all three were not available.
High risk of CVD was defined as having any of the following conditions: history of hypertension, coronary artery disease, stroke, diabetes,
age >55, former or current smoker.
All p-values for differences between groups were <0.001
BP, blood pressure; CVD, cardiovascular disease.

The all-cause mortality rate was 8.88% (8210/92435)
in all high-risk participants. It was higher, at 12.64% in
group 2 (age standardised rate 12.52%), and at 9.45%
in group 3 (age standardised rate 9.50%), compared
with 5.84% in group 1 (age standardised rate 5.99%). In
Cox proportional hazard models with participants from
group 1 (all three types of CVD medicines were available
and affordable) as the reference group, the risk of all-
cause mortality was also greater with both lack of availability and/or affordability. Compared with group 1, the
risk of all-cause mortality was greater in group 2, with the
Chow CK, et al. BMJ Global Health 2020;5:e002640. doi:10.1136/bmjgh-2020-002640

adjusted HR=1.20, 95% CI 1.08 to 1.32, p<0.001 and in
group 3, with the adjusted HR=1.25, 95% CI 1.04 to 1.50,
p=0.015 (figure 3).
The percentages (95% CI) of MACEs and mortality
by availability and affordability during follow-
up are
presented in online supplemental appendix table S3.
Unadjusted HRs for MACEs and all-cause mortality by
availability and affordability are shown in online supplemental appendix table S4.
Similar results were found through sensitivity analyses using different age thresholds (>60 or>65, online
5

BMJ Global Health

Figure 1 Percentages of individuals with high CVD risk from communities where three types of CVD medicines are available
(left) and affordable (right). CVD, cardiovascular disease; HIC, high-income countries; LICs, low-income countries; LMICs, lower
middle-income countries; UMICs, upper middle-income countries.

supplemental appendix table S5 and S6), different
thresholds for capacity to pay (10% or 25%, online
supplemental appendix tables S7‒S9) and different definition of high risk individual (the non-laboratory INTERHEART risk score,17 online supplemental appendix
tables S10‒S13).
The number of medicines available among the 10
studied medications varied considerably (online supplemental appendix figure S1). For each additional drug
available, the hazard of MACEs reduced by 5% (95% CI
0.93 to 0.98, p<0.001) (online supplemental appendix
figure S2).
Affordability was a key factor across countries from
all income categories. For people living in HICs, the

Figure 2 Availability and affordability of three types of
CVD medicines and MACEs (group 1 was the reference
group). CVD, cardiovascular disease; MACE, major adverse
cardiovascular events.

6

impact of affordability on MACEs appeared even higher
compared with those living in middle-income countries
and LICs. Online supplemental appendix figure S3 presents the adjusted HRs of affordability (not affordable vs
affordable) on time to MACEs for each economic group.

DISCUSSION
In this study, we found that essential CVD medicines were
unavailable and unaffordable for a large proportion of
communities where the individuals with high risk of CVD
were living, particularly in LMICs and LICs. The unavailability and unaffordability of essential CVD medicines was
associated with increased risk of MACEs after accounting

Figure 3 Availability and affordability of three types of CVD
medicines and mortality (group 1 was the reference group).
CVD, cardiovascular disease.
Chow CK, et al. BMJ Global Health 2020;5:e002640. doi:10.1136/bmjgh-2020-002640
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for sociodemographic and economic factors, education,
comorbidities and accounting for clustering.
Low availability and affordability to cardiovascular
medicines in LICs and middle-
income countries have
been reported in several studies. In a study published in
2010, van Mourik et al found that the overall availability
of cardiovascular medicines in 36 countries at all levels
of development was poor (26.3% in public sector, 57.3%
private sector) and cardiovascular medicines were least
affordable in the poorest countries.18 In a survey of availability and affordability of selected essential medicines
for chronic diseases in LICs and middle-income countries conducted by Mendis et al in 2007, the availability
of some essential CVD medicines was extremely low in
some countries (eg, hydrochlorothiazide: 0.7% in Pakistan, 5.8% in Bangladesh; captopril: 0.5% in Nepal, 5.6%
in Malawi; enalapril: 0.8% in Malawi; and statin: ranged
from 0.1% to 21% in the all the surveyed countries), and
the affordability of these medicines was also poor.4 In
another study of hypertension management in 44 LICs
and middle-
income countries, only 29.9% of people
with hypertension received antihypertensive treatment,
and in only 10.3% was it controlled.19 In a recent study
conducted by Husain et al based on the WHO online
repository of national essential medicines lists for 53
countries, the average availability of the essential CVD
medications was 54% in LICs and lower-middle-income
countries (LMICs) and 60% in HICs and upper-middle-
income countries (UMICs).20 They also found that
affordability was lower in LICs and LMICs than HICs and
UMICs for both brand and generic medications.20 In our
previous publications from the PURE study, overall hypertension control was worst in LICs and LMICs (10.8%),
with poor access to medicines among the reasons for the
low frequency of treatment and control of hypertension
in these countries.6 21 The data in the majority of these
studies are now dated, we need repeat assessments to
track medication availability and affordability as these
could change over time.
Interestingly, in contrast to our anticipation, the
crude rates of MACEs and all-cause mortality were actually higher in group 2 compared with group 3. Group 2
comprised of participants with high risk of CVD that lived
in communities where essential CVD medicines were
available but unaffordable to them. This may be due to
the higher prevalence of comorbidities such as hypertension and diabetes in this group. In addition, the proportion of urban living was also higher in group 2 compared
with group 3 (57.6% vs 28.1%, respectively). Urban living
may be associated with other factors that can increase
the risk of MACEs and all-cause mortality such as anxiety,
depression, sedentary lifestyle, high consumption of fast
food and diseases related to air pollution, especially in
LICs and middle-income countries. This finding may also
highlight the fact that affordability was a key factor. Even
when the medications are available in the communities,
people still could not access them if they could not afford
them. In this study, the impact of affordability on MACEs
Chow CK, et al. BMJ Global Health 2020;5:e002640. doi:10.1136/bmjgh-2020-002640

in people living in HICs was even higher compared with
those living in LICs and middle-
income countries, as
shown in the online supplemental appendix figure S3.
Strengths
Our analyses are unique because we used standardised
methods to assess availability, affordability and event rates
of MACEs and all-cause mortality from 21 countries and
592 urban and rural communities worldwide.
Our results support previous ﬁndings that in LICs and
middle-
income countries, the availability and affordability of key medicines for the prevention of CVD are
low and provide evidence that this affected adversely on
outcomes in populations at risk of CVD.
Limitations
As noted in previous publications from the PURE study,
our results capture only part of the costs of treatment,3
as we are unable to take into account other costs (such
as professional fees or travel or time taken of work to visit
a doctor) and hence, we could have overestimated its
affordability. In addition, we were also unable to account
for policies and other activities of non-governmental organisations in various regions of the world that may provide
free medications to some participants in some countries,
which may influence medication use and access to variable
degrees. We do not have information about how household
incomes might have changed during follow-up, which may
be important given the economic impact of illness. Also,
availability and affordability were only assessed at baseline (but this is inevitable in such a large study in which
we aimed to relate these to long-term outcomes) and may
have changed over time. Moreover, during the study time,
several countries transitioned to other income categories,
for example, India: LIC–LMIC (2009), China: LMIC–
UMIC (2013), Colombia: LMIC–UMIC (2008), Iran:
LMIC–UMIC (2010). Along with these transitions, their
health systems may have changed as well. The availability
and affordability of medicines were assessed at the community pharmacy level, therefore it may not necessarily reflect
the availability and affordability at different points of care
such as pharmacies at public health facilities or private
health facilities. The criteria that EPOCH used to collect
medicine price entailed surveying the most common trade
name for each of these medicine classes identified by the
pharmacists. While our method attempted to identify the
most available medicine in the pharmacy and its cost, there
is variation in availability and price particularly between
generic and brand drugs across pharmacies. Availability of
a particular CVD medicine may also depend whether the
country Essential Medicine Lists include the medicines
in the first place. In addition, there may be other aspects
of access to healthcare that may have changed, such as
number of health workers, availability of diagnostic and
therapeutic interventions and we do not have data on
these. The criteria used to define high risk patients resulted
in having a mixed group of patients that are not at the same
level of risk. For the various reasons described above, the
7
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HRs calculated in these analyses could be underestimated
compared to an analysis in which availability and affordability was more more accurately measured.

pre-existing CVD was consistently associated with significantly worse outcome in patients with COVID-19.26

Implications for practice/policy
The medicines studied in this paper have been shown to
be effective in primary and secondary prevention of CVD
events and to reduce mortality, and are recommended in
most clinical guidelines but were unavailable in a large
proportion of communities in LICs and middle-income
countries and even when available they were not always
affordable. In a previous publication from the PURE study,
both low availability and affordability were associated with
low use of CVD medicines.3 This points to a plausible explanation of the association with MACEs and mortality.
According to the WHO, essential medicines are those
that satisfy the priority healthcare needs of the population.22 Essential medicines should be available within
functioning health systems at all times, in adequate
amounts, in the appropriate dosage, with assured quality
and at an affordable price to individuals and communities.22 The WHO’s Global Action Plan set a target of 80%
availability of affordable essential medicines for non-
communicable diseases worldwide, and at least 50% of
those in need of these medicines by 2025.23 This requires
addressing the most common reasons for medicines
shortages, catalogued in a review conducted by Acosta
et al.24 These include market-
related factors (such as
increased demand, voluntary withdrawal, unexpected
changes in clinical practice, loss of market interest and
relocation of production facilities), supply chain management (structure of the network or supply chain in the
country, supply of raw materials and excipients), manufacturing processes (quality concerns, changes in the
product formulation, industrial development capacities,
production problems), reduced public health funding,
political and ethical issues (such as regulatory problems,
public policy and social conflicts). In LICs and middle-
income countries, the rising prices of medicines, often
paid out-of-pocket, mean that they account for up to 70%
of total healthcare expenditure24 and can lead to illness-
induced poverty and reduce access to the needed treatment. More research effort and strategies are needed to
improve affordability to essential medicines. In a recent
publication from the Heart Outcomes Prevention and
Evaluation 4 (HOPE-4) study in individuals with new or
poorly controlled hypertension from 30 communities in
Colombia and Malaysia, free distribution of a fixed dose
combination of two antihypertensive drugs and statins
substantially improved the Framingham risk score and
improved the control of hypertension and low-density
lipoprotein (LDL) cholesterol in the participants.25
Ensuring access to essential medicine plays a major role
in the prevention and control of CVD, which is both
important to prevent long-term adverse outcomes and
also essential during the current COVID-19 pandemic
situation. According to a recent review, the presence of

CONCLUSIONS
Less availability and affordability of essential CVD medicines were associated with increased risk of MACE and
all-cause mortality in this global population from countries of varying income levels. These findings highlight the
importance of ensuring that essential CVD medicines are
available and affordable for those at high risk of CVD everywhere. Factors associated with availability and affordability
of essential CVD medicines must be identified for appropriate care globally.
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